Regeneration as a treatment pathway
The platform combines biology, engineering and computation to develop tunable therapies targeting inflammation and fibrosis. Kuragenx is the lead eye-treatment programme; other development work addresses damage to lung, liver and nervous-system tissues.
Preparing a manufacturing network
AGC Biologics in Italy is a manufacturing partner for US and European markets. A collaboration with Nucelion Therapeutics in India supports Asia-Pacific supply, while potential Middle Eastern partnerships remain under exploration.
Where the funding goes
- Clinical development of regenerative therapies
- Manufacturing scale-up
- Expansion across the US, Japan and the Middle East